Compare Summit Therapeutics Inc (SMMT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Summit Therapeutics Inc trades at $14.57 (market cap $10.48B), while State Street SPDR S&P Biotech ETF trades at $154.49. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SMMT | XBI | |
|---|---|---|
Market Cap | $10.48B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $29.32 | $164.28 |
52-Week Low | $13.05 | $85.16 |
Enterprise Value | $9.90B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
